(STIM) Neuronetics - Overview
Stock: Transcranial Magnetic Stimulation, Neurohealth Treatment, Office-Based Therapy
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 151% |
| Relative Tail Risk | -18.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.46 |
| Alpha | -77.49 |
| Character TTM | |
|---|---|
| Beta | 1.828 |
| Beta Downside | 1.695 |
| Drawdowns 3y | |
|---|---|
| Max DD | 89.72% |
| CAGR/Max DD | -0.38 |
Description: STIM Neuronetics December 31, 2025
Neuronetics, Inc. (NASDAQ: STIM) commercializes the NeuroStar Advanced Therapy System, a non-invasive, office-based transcranial magnetic stimulation (TMS) device approved for treating adult patients with major depressive disorder (MDD). The system generates MRI-strength magnetic pulses to stimulate brain regions implicated in mood regulation, and the company distributes the device directly to psychiatrists through a dedicated sales and support organization. Neuronetics was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Key quantitative signals (as of the most recent 10-K filing) include FY 2023 revenue of approximately $73 million, a 12 % year-over-year increase driven primarily by higher device shipments and expanded service contracts. The installed base of NeuroStar systems surpassed 2,300 units worldwide, reflecting steady adoption in both U.S. and international markets. A sector-wide driver is the growing reimbursement landscape: Medicare’s 2022 decision to cover TMS for treatment-resistant depression has expanded the addressable market, which analysts estimate will grow at a 6-8 % CAGR through 2028 as mental-health spending rises and clinicians seek alternatives to pharmacotherapy.
For a data-rich, model-based perspective on STIM’s valuation and risk profile, consider reviewing the detailed analysis on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -44.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.21 > 0.02 and ΔFCF/TA 9.39 > 1.0 |
| NWC/Revenue: 27.68% < 20% (prev 50.28%; Δ -22.60% < -1%) |
| CFO/TA -0.21 > 3% & CFO -29.9m > Net Income -44.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (67.3m) vs 12m ago 122.4% < -2% |
| Gross Margin: 50.43% > 18% (prev 0.76%; Δ 4967 % > 0.5%) |
| Asset Turnover: 118.3% > 50% (prev 98.10%; Δ 20.19% > 0%) |
| Interest Coverage Ratio: -4.92 > 6 (EBITDA TTM -34.1m / Interest Expense TTM 7.57m) |
Altman Z'' -14.93
| A: 0.25 (Total Current Assets 64.9m - Total Current Liabilities 28.9m) / Total Assets 145.5m |
| B: -3.10 (Retained Earnings -451.6m / Total Assets 145.5m) |
| C: -0.34 (EBIT TTM -37.3m / Avg Total Assets 109.8m) |
| D: -3.95 (Book Value of Equity -450.9m / Total Liabilities 114.1m) |
| Altman-Z'' Score: -14.93 = D |
Beneish M -2.14
| DSRI: 0.56 (Receivables 19.2m/19.3m, Revenue 129.9m/72.7m) |
| GMI: 1.50 (GM 50.43% / 75.70%) |
| AQI: 1.57 (AQ_t 0.35 / AQ_t-1 0.23) |
| SGI: 1.79 (Revenue 129.9m / 72.7m) |
| TATA: -0.10 (NI -44.5m - CFO -29.9m) / TA 145.5m) |
| Beneish M-Score: -2.14 (Cap -4..+1) = BB |
What is the price of STIM shares?
Over the past week, the price has changed by -25.36%, over one month by -7.69%, over three months by -38.10% and over the past year by -56.18%.
Is STIM a buy, sell or hold?
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the STIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.5 | 316.7% |
| Analysts Target Price | 6.5 | 316.7% |
| ValueRay Target Price | 1.2 | -25% |
STIM Fundamental Data Overview February 05, 2026
P/B = 4.982
Revenue TTM = 129.9m USD
EBIT TTM = -37.3m USD
EBITDA TTM = -34.1m USD
Long Term Debt = 65.7m USD (from longTermDebt, last quarter)
Short Term Debt = 5.58m USD (from shortTermDebt, last quarter)
Debt = 90.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 56.3m USD (from netDebt column, last quarter)
Enterprise Value = 180.7m USD (124.6m + Debt 90.7m - CCE 34.6m)
Interest Coverage Ratio = -4.92 (Ebit TTM -37.3m / Interest Expense TTM 7.57m)
EV/FCF = -5.92x (Enterprise Value 180.7m / FCF TTM -30.6m)
FCF Yield = -16.90% (FCF TTM -30.6m / Enterprise Value 180.7m)
FCF Margin = -23.52% (FCF TTM -30.6m / Revenue TTM 129.9m)
Net Margin = -34.27% (Net Income TTM -44.5m / Revenue TTM 129.9m)
Gross Margin = 50.43% ((Revenue TTM 129.9m - Cost of Revenue TTM 64.4m) / Revenue TTM)
Gross Margin QoQ = 45.87% (prev 46.60%)
Tobins Q-Ratio = 1.24 (Enterprise Value 180.7m / Total Assets 145.5m)
Interest Expense / Debt = 2.29% (Interest Expense 2.08m / Debt 90.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -29.5m (EBIT -37.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.24 (Total Current Assets 64.9m / Total Current Liabilities 28.9m)
Debt / Equity = 3.32 (Debt 90.7m / totalStockholderEquity, last quarter 27.4m)
Debt / EBITDA = -1.65 (negative EBITDA) (Net Debt 56.3m / EBITDA -34.1m)
Debt / FCF = -1.84 (negative FCF - burning cash) (Net Debt 56.3m / FCF TTM -30.6m)
Total Stockholder Equity = 29.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -40.53% (Net Income -44.5m / Total Assets 145.5m)
RoE = -151.3% (Net Income TTM -44.5m / Total Stockholder Equity 29.4m)
RoCE = -39.21% (EBIT -37.3m / Capital Employed (Equity 29.4m + L.T.Debt 65.7m))
RoIC = -33.72% (negative operating profit) (NOPAT -29.5m / Invested Capital 87.3m)
WACC = 8.08% (E(124.6m)/V(215.4m) * Re(12.65%) + D(90.7m)/V(215.4m) * Rd(2.29%) * (1-Tc(0.21)))
Discount Rate = 12.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 52.22%
Fair Price DCF = unknown (Cash Flow -30.6m)
EPS Correlation: 63.03 | EPS CAGR: 73.27% | SUE: 1.04 | # QB: 1
Revenue Correlation: 83.92 | Revenue CAGR: 27.44% | SUE: -0.30 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.13 | Chg30d=-0.010 | Revisions Net=-2 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.47 | Chg30d=-0.010 | Revisions Net=-2 | Growth EPS=+20.8% | Growth Revenue=+10.8%